E Fund Management Co., Ltd. Arcus Biosciences, Inc. Transaction History

E Fund Management Co., Ltd.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$14.83 - $20.18 $37,831 - $51,479	2,551 Added 18.89%	16,052 $303,000
Q4 2023 Feb 06, 2024	SELL	$13.43 - $19.63 $20,641 - $30,171	-1,537 Reduced 10.22%	13,501 $257,000
Q3 2023 Nov 13, 2023	SELL	$17.62 - $23.54 $19,346 - $25,846	-1,098 Reduced 6.8%	15,038 $270,000
Q2 2023 Aug 11, 2023	SELL	$16.97 - $22.03 $122,167 - $158,593	-7,199 Reduced 30.85%	16,136 $328,000
Q1 2023 May 11, 2023	BUY	$15.96 - $23.15 $209,411 - $303,751	13,121 Added 128.46%	23,335 $426,000
Q4 2022 Feb 14, 2023	SELL	$19.7 - $35.71 $108,468 - $196,619	-5,506 Reduced 35.03%	10,214 $211,000
Q3 2022 Nov 14, 2022	SELL	$23.23 - $30.07 $47,737 - $61,793	-2,055 Reduced 11.56%	15,720 $411,000
Q2 2022 Aug 15, 2022	BUY	$17.23 - $37.73 $166,614 - $364,849	9,670 Added 119.31%	17,775 $450,000
Q1 2022 May 12, 2022	BUY	$28.92 - $41.83 $124,384 - $179,910	4,301 Added 113.07%	8,105 $256,000
Q1 2021 May 12, 2021	BUY	$26.16 - $41.39 $99,512 - $157,447	3,804 New	3,804 $106,000

196

51.6M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $906M
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on E Fund Management Co., Ltd. with notifications on news.